<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715648</url>
  </required_header>
  <id_info>
    <org_study_id>003-2016</org_study_id>
    <nct_id>NCT02715648</nct_id>
  </id_info>
  <brief_title>Using Phenazopyridine for In-office Cystoscopy</brief_title>
  <official_title>Using Phenazopyridine for In-office Cystoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Urogynecology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Urogynecology Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to conduct a randomized controlled trial to evaluate whether
      administration of phenazopyridine prior to the procedure decreases office cystoscopy time.
      Women undergoing in-office cystoscopy at Boston Urogynecology will be recruited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All potentially eligible participants will have had a complete history, physical examination,
      urinalysis and urine culture for clinical purposes. After eligibility is confirmed and
      written, informed consent is obtained, participants will be randomized to one of the two
      study arms. Participants randomized to phenazopyridine arm will receive 200 mg by mouth
      approximately 60 minutes prior to the scheduled cystoscopy. During the cystoscopy, at various
      time points, the time will be recorded.The color of the efflux will also be documented.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total cystoscopy time</measure>
    <time_frame>at time of cystoscopy</time_frame>
    <description>The total time of cystoscopy will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to visualization of ureteral jets</measure>
    <time_frame>at time of cystoscopy</time_frame>
    <description>The time to visualization of the first ureteral jet will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Cystoscopy</condition>
  <condition>Phenazopyridine</condition>
  <arm_group>
    <arm_group_label>No Phenazopyridine before cystoscopy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will not receive phenazopyridine prior to cystoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenazopyridine before cystoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive 200mg of phenazopyridine prior to cystoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenazopyridine</intervention_name>
    <arm_group_label>Phenazopyridine before cystoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients undergoing in-office diagnostic cystoscopy at Boston Urogynecology
             Associates

        Exclusion Criteria:

          -  Women who have taken vitamin B the day of the cystoscopy

          -  Cystoscopy with concurrent treatments such as botulinum toxin or periurethral bulking
             injections

          -  Allergy to phenazopyridine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eman Elkadry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Practitioner</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Rogers</last_name>
    <phone>617-354-5452</phone>
    <email>krogers2@mah.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Urogynecology Associates, 725 Concord Ave. Suite 1200</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Urogynecology Associates</investigator_affiliation>
    <investigator_full_name>Eman Elkadry, M.D.</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

